RegCell is a cutting-edge company that has established a new immune system control technology, providing innovative medical solutions for autoimmune diseases and cancer. Their mission is to develop high-functioning stable iTreg (S/F-iTreg) cells, leading the way in Treg development. With a vision to offer safe and highly effective treatments, RegCell aims to suppress the progression of difficult-to-treat autoimmune diseases, inflammatory disorders, and transplant rejection.

They strive to achieve their goals by enabling antigen-specific immune suppression, minimizing the need for frequent or long-term administration, and fundamentally treating immune-related conditions. Founded by renowned immunologist Dr. Shimon Sakaguchi, the discoverer of Treg cells, RegCell focuses on converting disease-inducing T cells into potent antigen-specific Treg cells to control and heal autoimmune diseases.

Their innovative cellular therapy aims to establish a reliable treatment for immune-related conditions, benefiting patients worldwide. Under the leadership of President Yasuhiko Handa, RegCell is committed to harnessing the incredible power of the immune system and providing hope for a brighter future